Clinical Trials

Phase NA Enrolling by invitation

Breast Neoplasms, Lymphatic Metastasis

NCT07586319 2026-05-19

SASI-MBC

110 enrolled

Breast Neoplasms

NCT02926911 2026-05-12

COMET

997 enrolled 16 charts

Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Ductal

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

235 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT00911911 2026-03-13

SPAM

66 enrolled

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT06135714 2026-02-11

OLIGAMI

Phase 3 Recruiting

340 enrolled

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT05278741 2025-12-26

BREAST

32 enrolled

Breast Neoplasms

NCT00314405 2025-12-22

Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope

100 enrolled

Breast Neoplasms

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

35 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Phase NA Not yet recruiting

Breast Neoplasms

NCT07253168 2025-11-28

TIGER-BC

240 enrolled

Breast Neoplasms

NCT05890677 2025-11-14

LYMPH

Phase NA Recruiting

280 enrolled

Breast Cancer Lymphedema

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Phase 3 Recruiting

2,400 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Triple Negative Breast Neoplasms

NCT02807597 2025-08-17

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

Phase 1/2 Terminated

9 enrolled 5 charts

Breast Neoplasms

NCT07071402 2025-08-15

A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

Phase NA Recruiting

120 enrolled

Breast Neoplasms

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2 Recruiting

27 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

1,240 enrolled

Breast Neoplasms

NCT06666517 2025-03-13

PERICAFS

69 enrolled

Breast Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

NCT06716073 2024-12-04

Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial

Phase NA Recruiting

1,380 enrolled

Breast Cancer Invasive

NCT00182728 2024-10-01

NRR

89 enrolled 10 charts

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT01015625 2024-08-19

POSYTIVE

90 enrolled 16 charts

Breast Neoplasms, Neoplastic Cells, Circulating

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 1 FDA

Breast Neoplasms

NCT03982485 2024-04-30

APP

196 enrolled

Breast Neoplasms

NCT04997941 2024-04-23

MORE-T

238 enrolled

Premenopausal Breast Cancer

NCT04629846 2024-04-19

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

517 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT02620280 2024-03-06

NeoTRIPaPDL1

278 enrolled

Phase 3 Active not recruiting

Carcinoma, Ductal, Breast, Triple Negative Breast Neoplasms

NCT03595592 2024-03-06

APTneo

650 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Invasive Breast Cancer

NCT06281860 2024-02-28

PITHAC

Phase 1 Unknown

39 enrolled

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01717131 2024-01-11

Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node

2,228 enrolled

Invasive Breast Cancer

NCT02636582 2023-12-05

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

43 enrolled 10 charts

Carcinoma, Intraductal, Noninfiltrating

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast Neoplasms

NCT05981001 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1/2 Recruiting

170 enrolled

Phase 4 Not yet recruiting

Breast Neoplasms

NCT05843292 2023-06-06

NeoSTEP

48 enrolled

Triple Negative Breast Neoplasms

NCT02586025 2023-05-22

PEONY

329 enrolled 33 charts

Breast Neoplasms

NCT02891759 2023-05-06

Compare Outcomes Between Two Acellular Dermal Matrices

320 enrolled

Breast Neoplasms

NCT03578380 2023-04-18

Supermicrosurgery for Breast Cancer Survivors With Lymphedema.

Phase NA Unknown

100 enrolled

Breast Neoplasms

NCT03916744 2023-03-10

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Phase 1 Completed

75 enrolled 24 charts

Breast Neoplasms

NCT04436744 2023-02-02

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

221 enrolled 21 charts

Breast Neoplasms

NCT02400658 2023-01-25

Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer

358 enrolled

Breast Neoplasms

NCT04698252 2022-08-08

LARA

Phase 2 Recruiting

74 enrolled

Breast Neoplasms

NCT04079049 2022-05-25

BreCLIM-2

Phase 3 Recruiting

200 enrolled

Breast Neoplasms

NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

216 enrolled

Breast Cancer Invasive

NCT01847001 2021-09-10

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

10 enrolled 12 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

429 enrolled